10 domestic new crown epidemic seedlings data revealed, who can "kerong"?

The continuous mutation of the new crown virus has made it more difficult for global epidemic prevention work, and it has also created a new problem
for epidemic enterprises.
The reason is that the constantly mutating strain will make the new crown epidemic "obsolete" and lead to insufficient
protection.

Of course, this is both a challenge and an opportunity
for epidemic enterprises.
The constant mutation of strains means that the development of a new generation of coronavirus seedlings is imperative
.

In overseas markets, a new generation of Omicron vaccines is gradually emerging
.

Looking at China, the new crown epidemic seedlings are also about to enter the 2.
0 era, including more than 20 epidemic seedling enterprises such as Watson Biotechnology, CSPC Pharmaceutical Group, Rico Biotechnology, and Zhifei Biotechnology, all of which have potential to be effective against Omicron
.

In the face of menacing mutated viruses, the crisis and opportunity of epidemic enterprises are on
the front line.
At present, data on more than 10 epidemic seedlings have been released, allowing us to get a glimpse of their future potential
.

So, who are you most optimistic about?

       / 01 /

Lizhu Group:

Recombinant protein disease V-01

Lizhu Group's V-01 is a recombinant protein seedling, which consists of
four parts: interferon, Pan epitope, RBD dimer and Fc fusion protein.

Since the V-01 antigen structure incorporates human interferon as a biological adjuvant, there is a possibility
to enhance the level of viral neutralizing antibodies and cellular response.

So, how did the V-01 actually perform?

On June 8, 2022, Lizhu Group disclosed the Phase 3 clinical data
of V-01 in Pakistan and Malaysia in EMI Magazine.

The clinical protocol is to sequentially strengthen V-01 on the basis of two doses of inactivated vaccines, and the relative protective force standard is used to measure the effect
of the epidemic seedlings.

The final data shows that the overall protection rate of V-01 is 47.
8%.

By age group, V-01 has a protection rate of 48.
5% for 18-59 years olds and 24.
3%
for people aged 60 and above.

According to the virus subtype, V-01 has a 47% protection rate against the Omicron strain and 79.
9%
protection against the Delta strain.

       / 02 /

Kangtai Biotech:

Inactivated disease seedling KCONVAC

In the field of inactivated epidemic seedlings, Kangtai Biotech is a player
who came out on top.

In May 2021, Kangtai Bioinactivated Disease Seedling KCONVAC was included in emergency use
.
On November 18, 2022, Kangtai Biotech announced the latest phase III.
international multi-center clinical study data
through an announcement.

As of the company's data analysis date, 30,881 people
were actually enrolled in the clinic.
The results show:

The protective efficacy of the epidemic against confirmed new crown cases of any severity is 51.
54%, and the protective effect of severe cases and above cases and deaths is 100%.

From the perspective of strain typing, KCONVAC has the potential
to fight Omicron.
According to the genotyping results of the endpoint cases that had completed sequencing, Omicron strain accounted for 92.
29% and Delta strain accounted for 7.
71%.

However, the company did not specifically disclose the protection rate data
for Omicron beads and Delta beads.

       / 03 /

Zhifei Bio:

Recombinant protein seedling ZF2001

In the field of recombinant protein seedlings, Zhifei Biology is one of the
leaders.

In early March 2022, the first-generation recombinant protein epidemic seedling ZF2001 of Zhifei Biotechnology was urgently approved for use and has now been used for the third dose of sequential strengthening
.

According to phase III data, the protection rate against the Delta variant is 81.
4%, and the protection rate against the alpha variant is 92.
7%.

So, how effective is the vaccine against the Omicron strain?

At present, Zhifei Bio has disclosed the level
of neutralizing antibody titers against the Omicron strain.

For the Omicron strain, after 14 days of booster vaccination, the neutralizing antibody titer of the prototype strain increased by 11.
3 times, and the positive conversion rate was 91.
33%;

In the detection of neutralizing antibodies against pseudoviruses, the neutralizing antibody titers against Omicron BA.
2.
12.
1 strain increased by 5.
5 times and Omicron BA.
4/5 strain increased by 3.
3 times
.

Based on the first generation of recombinant protein seedlings, Zhifei Bio developed the second-generation seedlings ZF2202 (Omicron-Delta chimeric disease), according to public reports, ZF2202 is expected to read out data
in January next year.

       / 04 /

Shenzhou Cells:

Recombinant protein disease seedlings SCTV01C/SCTV01E

Shenzhou Cell is a contestant
of innovative pharmaceutical companies in the cross-circle of new crown epidemic seedlings.

The company has developed two new crown epidemic seedlings
, SCTV01C/SCTV01E.
Among them, SCTV01C has been authorized for emergency use against the Alpha/Beta variant; SCTV01E targets the Alpha/Beta/Delta/Omicron variant
.

At present, the company has disclosed some data on SCTV01C/SCTV01E UAE continuation enhancement phase III clinical trial and Pfizer mRNA epidemic emergent clinical trial
.

The UAE Phase III clinical data show:

For BA.
1 strains, the SCTV01C neutralizing antibody titer was 4.
52 times that of inactivated infected seedlings, and the SCTV01E neutralizing antibody titer was 8.
79 times
that of inactivated infected seedlings.

For BA.
5 strains, the SCTV01E neutralizing antibody titer was 6.
79 times that of inactivated infected seedlings, and the SCTV01E neutralizing antibody titer was 8.
13 times
that of inactivated infected seedlings.

In the subgroup of head-to-head mRNA (primary immunizations are mRNA vaccines):

For BA.
1 strains, the SCTV01C neutralizing antibody titer was 1.
13 times that of mRNA vaccines, and the SCTV01E neutralizing antibody titer was 1.
58 times
that of mRNA vaccines.

For BA.
5 strains, the SCTV01C neutralizing antibody titer was 1.
02 times that of mRNA vaccines, and the SCTV01E neutralizing antibody titer was 1.
35 times
that of mRNA vaccines.

       / 05 /

Rico Biotech:

Recombinant protein disease seedlings ReCOV

Although it is a new-generation epidemic seedling enterprise, Rico Biotech has shown good strength
in the competition of new crown epidemic seedlings.

Rico Biotech has laid out two new coronavirus seedlings, namely lyophilized mRNA seedlings and recombinant protein seedlings ReCOV
.
Among them, the leading progress is ReCOV, which is advancing a number of key phase III clinical work
.

ReCOV antigen adopts a conservative NTD-RBD-foldon trimer design; The new adjuvant is BFA03
against GlaxoSmithKline AS03.
Two major advantages, which bring potential advantages
such as high immunogenicity and broad spectrum.

The Phase 2 clinical data disclosed by the company shows that the peak of neutralizing antibodies after two doses of ReCOV can be as high as 4803.
4IU/mL
.
Under the same conditions, Moderna's mRNA-1273 was 1404.
2 IU/mL, and Pfizer's BNT162b2 was 928.
8 IU/mL
.

In the face of the mysterious keron strain, ReCOV is also undaunted
.

Compared with the prototype strain, the level of neutralizing antibodies against Omicron BA.
2, BA.
4/5 and BA.
2.
75 decreased by about 1.
6-2 times, 2.
2-3.
5 times and 2.
6-3 times, respectively, which was significantly lower than the published foreign mRNA disease data.

Compared with subjects vaccinated with the third dose of inactivated disease as homologous booster immunization, the growth factor of neutralizing antibody titers against prototype strains and Omicron variants BA.
2, BA.
4/5 and BA.
2.
75 was 12.
1-17.
3 times, which was significantly higher than that of other domestic vaccines
.

       / 06 /

Clover:

Recombinant protein disease seedlings SCB-2019

Like Rico Biologics, Clover is also a new-generation epidemic seedling enterprise, and its core product SCB-2019 is also a recombinant protein epidemic seedling
.

However, the choice of adjuvants between the two companies is slightly different, and Clover uses imported CpG1018/aluminum adjuvant
.

Currently, SCB-2019 discloses data
from 2 dimensions.

First, SCB-2019 as a heterologous third dose in subjects previously vaccinated with two doses of inactivated vaccine
.
For the Omicron strain, SCB-2019 induced about 6 times higher levels of neutralizing antibodies than the third dose of inactivated vaccine
.

Second, the protective effect
of new crown infection in household contacts.
According to the company, SCB-2019 was able to reduce the transmission rate of new coronavirus infection among household contacts by 84%.

       / 07 /

Wantai Biotech:

Nasal spray of the new crown epidemic seedlings

Wantai Biotech, which has harvested a market value of hundreds of billions through HPV seedlings, has also participated in the competition
in the new crown epidemic seedling market.
It has taken a different approach and developed non-injectable nasal spray seedlings, hoping to gain a place
.

The nasal spray new crown virus was developed by inserting the RBD gene fragment of the new coronavirus spike protein using double attenuated influenza A virus as a vector
.

On October 10, Wantai Biotech announced the key data of its nasal spray new crown epidemic seedling phase III.
clinical trial:

For people with no history of immunization, the absolute protective efficacy of nasal spray within 3 months after immunization was 55%;

For people with a history of immunization, the absolute protection of nasal spray within 6 months after booster immunization was 82%.

According to the company's announcement, the genotyping results of the endpoint cases that have completed sequencing are all Omicron strains, specifically BA.
2 (42%), BA.
4 (39%) and BA.
5 (18%)
.

This means that Wantai Biotech's nasal spray seedlings may have a certain protective effect
against Omicron.

       / 08 /

Watson Bio:

Novel coronavirus mRNA seedlings (S protein chimera)/AWcorn

In the field of new crown epidemic seedlings, Watson Bio is definitely the most obsessed player
in mRNA technology.

At present, the company has laid out two mRNA seedlings, namely AWcorn in cooperation with Aygen Biologics and the new crown mRNA epidemic seedlings (S protein chimera)
developed in cooperation with Lanque Biotechnology.

Among them, AWcorn is designed
for the original strain.
According to the company's previous sequential booster test data in Yunnan and Guangxi, people who received 2 doses of inactivated vaccine had a better effect on the third dose of AWcorn than inactivated vaccines:

Against the Delta and Omicron strains, neutralizing antibodies were 6.
5 and 4.
4 times
higher in the AWcorn group than in the inactivated group, respectively.

The new crown mRNA seedlings (S protein chimera) cooperated with Lanque Biotechnology are designed based on the Alpha variant and add three mutation sites of the Beta variant
.

However, according to the paper published by Blue Magpie Biologics, the epidemic is defined as a "broad-spectrum" epidemic seedling
.
At present, the new crown mRNA epidemic (S protein chimera) is in the phase III clinical stage, whether it is broad-spectrum let us wait and see
.

       / 09 /

CanSino:

Adenovirus vector disease Miuk Vesha

In the competition of the new crown epidemic, CanSino was one of
the first players to stand out.
At present, the company's adenovirus vector disease Miao Keweisha has been approved for homologous booster and sequential vaccination; Inhaled dosage forms are also approved for booster shots
.

So, what exactly is the effect of Kwesha exactly? According to the company's Phase 3 clinical data published in The Lancet in January 2022, Kwesha targeted the original strain:

After 14 days of vaccination, the overall effective rate was 63.
7%, and after 28 days of vaccination, the overall effective rate was 57.
5%; In terms of prevention of severe disease, the effective rate was 96% after 14 days of vaccination and 91.
7%
after 28 days of vaccination.

At different age stages, the effective rate of infection prevention in 18-44 years old group was 60.
9% after 28 days of vaccination.
62.
2% for those aged 45–59 and 17.
5%
for those over 60 years of age.

At present, clinical studies of the sequential continuation of the new coronavirus vector for inhalation are being carried out
.

According to a small-scale study disclosed in The Lancet in May, Omicron virus can induce a higher immune response
than inactivated vaccines.

       / 10 /

CSPC Pharmaceutical Group:

mRNA disease seedling SYS6006

In the competition of mRNA epidemic seedlings, CSPC is also a potential player
.

According to the company's caliber, the product is designed
for targeted antigen mutations according to the prevalence of the strain.
Preclinical studies have shown that the product has good immunoprotective efficacy
against the inclusion of Omicron.

So, how effective is it?

At present, the company has disclosed preliminary data for Phase 2 clinical trials
.
According to the announcement, the company has completed the sequential strengthening test, which is divided into groups I, II, A and B
.

Among them, groups I and II were mRNA seedlings with different doses, and the continuation of the vaccination of people who had completed 2-3 doses of inactivated disease was strengthened.
Groups A and B were mRNA seedlings with different doses, and the continuation of the population who had completed the vaccination of 3 doses of recombinant protein vaccine was strengthened
.

The data showed that after one dose of mRNA vaccine, the neutralization antibody titers in groups I and II were 21.
6 times and 22.
5 times higher than those of inactivated homologous booster immunization.
The neutralized antibody titers in groups A and B were 14.
1- and 12.
7-fold
higher than those of inactivated homologous boosters, respectively.